Flow cytometry is a key technology in the investigation of and therapeutic development for infectious diseases. The ability to identify and characterize single cells based on cellular markers is crucial to understanding immune responses to pathogens and the development of therapeutics. Additionally, characterizing immune cell responses during cancer informs researchers as to ongoing changes in the tumor environment. Armed with this information, treatment for infections such as SARS-CoV-2 or personalized medicine approaches to cancer treatment can be developed on the foundation of flow cytometry.
This collection of articles presents a sampling of studies utilizing flow cytometry to better understand infectious diseases and develop diagnostic and therapeutic interventions. By introducing readers to the advantages of flow cytometry for diagnostic development and research into infectious disease, we hope to empower users to investigate the use of this technology to address their specific research or diagnostic goals.
What you will learn:
- Fundamentals of flow cytometry
- Diagnostic pipeline development and implementation
- Therapeutic development for infectious disease and cancer
Articles contained in the collection:
McKinnon, K. M. (2018). Flow cytometry: An overview. Current Protocols in Immunology, 120, 5.1.1–5.1.11.
Russell, E., et al (2021). Adapting to the Coronavirus Pandemic: Building and Incorporating a Diagnostic Pipeline in a Shared Resource Laboratory. Cytometry, 99: 90-99.
Nair, N, & Gomes-Solecki, M. (2020). A Mouse Model of Sublethal Leptospirosis: Protocols for Infection with Leptospira Through Natural Transmission Routes, for Monitoring Clinical and Molecular Scores of Disease, and for Evaluation of the Host Immune Response. Current Protocols in Microbiology, 59, e127.
Holbrook, A. K., et al (2019). CD4+ T cell Activation and Associated Susceptibility to HIV-1 Infection In Vitro Increased Following Acute Resistance Exercise in Human Subjects. Physiol Rep, 7 ( 18), e14234.
Nam, J., et al (2021). Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer Immunotherapy. Adv. Sci., 8, 2002577.
Brought to you by
Sponsored by
